ReviewActa pharmacologica Sinica2026
Solute carrier transporters as metabolic gatekeepers in tumor-microenvironment crosstalk.
Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) is a metabolically dynamic niche characterized by active metabolic crosstalk between tumor cells and various stromal and immune cell subsets, which critically influences tumor progression and therapeutic outcomes. Within this ecosystem, solute carrier (SLC) transporters are gatekeepers that mediate the transport of a wide range of metabolites, including nutrients, ions, and signaling molecules, across cellular membranes. SLC transporters have emerged as active regulators of TME composition and intercellular communication, representing promising yet underexplored therapeutic targets in cancer. This review highlights the central role of SLC transporters in orchestrating the competitive uptake of nutrients and the exchange of oncometabolites, thereby modulating immune responses, angiogenesis, and metabolic adaptation in the TME. By outlining strategies targeting SLC transporters for cancer therapy, this review also underscores the emerging potential of SLC transporters as therapeutic targets and offers a renewed perspective on targeting TME metabolism.
Indexed as
Identifiers
42151501What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.